[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:hepatitis-b-virus-hbsag-surface-protein-antigen":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Hepatitis B Virus HBsAg Surface Protein Antigen",10,8,[8,16,23,29,35,42,48,54,60,67],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06092333","VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B",[12],"Phase 2","RECRUITING","2026-08-26T02:19:05.360997Z","2026-07-24T01:27:14.928202Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07024641","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection",[20],"Phase 1","2026-08-26T02:19:19.162260Z","2026-05-05T02:43:29.364387Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04843852","TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B",[20],"2026-08-26T02:17:16.126291Z","2026-05-05T02:43:29.327590Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06963710","A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)",[12],"2026-08-03T01:56:45.025842Z","2026-05-05T02:43:28.740314Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT05417932","A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma",[39],"Phase 1\u002FPhase 2","2026-08-26T02:18:00.873391Z","2026-05-05T02:43:27.511518Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05856890","HepB mAb19 in Individuals With Chronic Hepatitis B Infection",[20],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:27.491318Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07654283","Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions",[12],"2026-08-26T02:16:39.977107Z","2026-06-17T19:21:16.688868Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06154278","Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B",[12],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:27.958288Z",{"nct_id":61,"title":62,"phases":63,"status":64,"updated_at":65,"content_modified":66},"NCT04954859","Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:07:45.344605Z","2026-05-05T02:43:29.709291Z",{"nct_id":68,"title":69,"phases":70,"status":64,"updated_at":71,"content_modified":72},"NCT02932150","Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection",[12],"2026-08-03T01:59:18.089574Z","2026-05-05T02:43:27.089722Z"]